Intellia Therapeutics, Inc. (LON:0JBU)
11.29
-0.50 (-4.24%)
Feb 12, 2026, 5:08 PM GMT
Intellia Therapeutics Revenue
Intellia Therapeutics had revenue of $13.78M USD in the quarter ending September 30, 2025, with 51.27% growth. This brings the company's revenue in the last twelve months to $57.53M, up 33.52% year-over-year. In the year 2024, Intellia Therapeutics had annual revenue of $57.88M with 59.55% growth.
Revenue (ttm)
$57.53M
Revenue Growth
+33.52%
P/S Ratio
23.09
Revenue / Employee
$142.75K
Employees
403
Market Cap
988.06M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 57.88M | 21.60M | 59.55% |
| Dec 31, 2023 | 36.28M | -15.85M | -30.40% |
| Dec 31, 2022 | 52.12M | 19.07M | 57.69% |
| Dec 31, 2021 | 33.05M | -24.94M | -43.01% |
| Dec 31, 2020 | 57.99M | 14.89M | 34.55% |
| Dec 31, 2019 | 43.10M | 12.67M | 41.63% |
| Dec 31, 2018 | 30.43M | 4.32M | 16.53% |
| Dec 31, 2017 | 26.12M | 9.64M | 58.49% |
| Dec 31, 2016 | 16.48M | 10.44M | 172.65% |
| Dec 31, 2015 | 6.04M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.64B |
| GSK plc | 32.67B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Spire Healthcare Group | 1.55B |
| CVS Group | 673.20M |
| HUTCHMED (China) | 439.54M |
| Oxford Nanopore Technologies | 204.69M |
Intellia Therapeutics News
- 6 days ago - Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 days ago - Intellia Therapeutics: 2 Major Catalysts Will Determine Stock's Trajectory In 2026 - Seeking Alpha
- 7 days ago - Notable Two Hundred Day Moving Average Cross - NTLA - Nasdaq
- 15 days ago - NTLA Stock Rating Maintained and Price Target Raised by HC Wainwright & Co. | NTLA Stock News - GuruFocus
- 16 days ago - FDA Lifts Hold on Intellia's Nexiguran Ziclumeran Program (NTLA) - GuruFocus
- 16 days ago - Intellia Moves Forward As FDA Removes Trial Hold For Rare Disorder - Benzinga
- 16 days ago - Intellia Moves Forward As FDA Removes Trial Hold For Rare Disorder - Benzinga
- 16 days ago - The Gene-Editing News That Sent Beleaguered Intellia Therapeutics Stock Up 10% - Investor's Business Daily